Shanghai Auson Pharmaceuticals Co.,Ltd was founded in 2019 by scientists with extensive experience in the pharmaceutical industry. Auson has two locations: Shanghai Auson is responsible for R&D, manufacture, clinical research and registration in China, while the Auson USA is responsible for manufacture, registration in USA and commercialization. 

Auson is committed to developing better medicines to fulfill unmet medical needs in China and overseas, including new dosage forms, new indications, and new dosing regimens. Our focusing therapeutic areas include vascular diseases, and anti-viral products development. The company’s priority is to create innovative therapeutics by using 505(b)(2) regulatory pathway in the U.S. and class 2 of drugs registration classification pathway in China, in the meantime to develop niche generic products.